Crossmark

Combined homologous recombination repair deficiency and immune activation analysis for predicting intensified responses of anthracycline, cyclophosphamide and taxane chemotherapy in triple-negative breast cancer

Crossref DOI link: https://doi.org/10.1186/s12916-021-02068-4

Published Online: 2021-09-01

Published Print: 2021-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Liao, Gaoming

Jiang, Zedong

Yang, Yiran

Zhang, Cong

Jiang, Meiting

Zhu, Jiali

Xu, Liwen

Xie, Aimin

Yan, Min

Zhang, Yunpeng

Xiao, Yun

Li, Xia
Funding

Funding for this research was provided by:

National Key R&D Program of China (2018YFC2000100)

National Natural Science Foundation of China (61873075, 32070673, 31871336)

Heilongjiang Provincial Natural Science Foundation (YQ2019C012)

Heilongjiang Postdoctoral Science Foundation (LBH-Q18099)

Program for Young Scholars with Creative Talents in Heilongjiang Province (UNPYSCT-2017059)
License Information

Text and Data Mining valid from 2021-09-01

Version of Record valid from 2021-09-01
More Information

Article History

Received: 8 May 2021

Accepted: 20 July 2021

First Online: 1 September 2021

Declarations

:

: This research has been conducted using publicly available datasets. De-identified data were used, and no ethical approval was required.

: Not applicable.

: The authors declare that they have no competing interests.

Document is current

Any future updates will be listed below